Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 4, 1999, Pages 595-600

  Michael, Roe ^a   Folkes, Adrian ^a   Ashworth, Philip ^a   Brumwell, Julie ^a   Chima, Lal ^a   Hunjan, Sukhjit ^a   Pretswell, Ian ^a   Dangerfield, Wendy ^a   Ryder, Hamish ^a   Charlton, Peter ^a  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; ANTHRANILIMIDE DERIVATIVE; BIRICODAR; DOXORUBICIN; ELACRIDAR; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; UNCLASSIFIED DRUG; VERAPAMIL; XR 9051; ZOSUQUIDAR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING KINETICS; DRUG POTENCY; DRUG PROTEIN BINDING; GLYCOPROTEIN SYNTHESIS; HUMAN; HUMAN CELL; INHIBITION KINETICS; MULTIDRUG RESISTANCE; STRUCTURE ACTIVITY RELATION;

ANTHRANILIC ACIDS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG SYNERGISM; HUMANS; P-GLYCOPROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0033593855     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00030-X     Document Type: Article

References (13)

1. 1. Gottesman, M.M.; Pastan, I. Annu Rev Biochem 1993, 62, 385.
2. 2. For a review on chemosensitisers see Boer, R.; Gekeler, V. Drugs of the Future 1995, 20, 499.
3. 3. Dale, I.L.; Tuffley, W.; Callaghan, R.; Holmes, J.A.; Martin, K.; Luscombe, M.; Mistry, P.; Ryder, H.; Stewart, A.J.; Charlton, P.; Twentyman, P.R.; Bevan, P. Br. J. Cancer 1998, 78, 885.
4. 4. Stewart, A.J.; Mistry, P.; Dangerfield, W.; Okiji, S.; Templeton, D. Annals of Oncology 1998, 9, 145.
5. 5. Mistry, P.; Bootle, D.; Liddle, C.; Loi, R.; Templeton, D. Annals of Oncology 1998, 9, 148.
6. 2 are detailed in international patent application number PCT/GB95/03029, UK application number 9426090.8.
7. 20; C 73.14%, H 5.88%, N 9.48%. Found C 73.17%, H 5.79%, N 9.44%.
8. 8. Sharp, T.M.; J. Chem. Soc. 1951, 2961.
9. 9. Dhainaut, A.; Régnier, G.; Atassi, G.; Pierre, A.; Léonce, S.; Kraus-Berthier, L.; Prost, J. F. J. Med. Chem. 1992, 35, 2481.
10. 10. Dodic, N.; Dumaitre, B.; Daugan, A.; Pianetti, P. J. Med. Chem. 1995, 38, 2418.
11. 11. Kajiji, S.; Dreslin, J. A.; Grizzuti, K; Gros, P. Biochemistry, 1994, 33, 5041.
12. 12. Germann, U. A.; Shlyakhter, D.; Mason, V. S.; Zelle, R. E.; Duffy, J. P.; Galullo, V.; Armistead, D. M.; Saunders, J. O.; Boger, J.; Harding, M. W. Anti-Cancer Drugs 1997, 8, 125.
13. 13. Dantzig, A. H.; Shepard, R. L.; Cao, J.; Law, K. L.; Ehlhardt, W. J.; Baughman, T. M.; Bumol, T. F.; Starling, J. J. Cancer Research, 1996, 56, 4171.